Growth Metrics

Lensar (LNSR) Total Debt (2019 - 2026)

Lensar (LNSR) reported Total Debt of $5.0 million for Q1 2026, down 75.25% on a QoQ basis from $20.2 million in Q4 2019.

Lensar (LNSR) has 2 years of Total Debt data on file, last reported at $5.0 million in Q1 2026.

  • Quarterly Total Debt changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2019 annual result came in at $20.2 million, changed N/A from the prior year.
  • Total Debt declined to $5.0 million in Q1 2026 per LNSR's latest filing, from $20.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $5.0 million in Q1 2026 and bottomed at $5.0 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 34.05 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 14.72 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 28.07 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 11.03 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 598.50 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 8.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.13 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 1.93 Bn
10 Lensar 69.32 Mn 69.61 Mn 6.38 Mn 5.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.00 Mn
Dec 31, 2019 20.20 Mn